cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.11663331.v2
title: Supplemental Data - Comprehensive profiling of Small RNAs in human embryo-conditioned culture media by improved sequencing and quantitative PCR methods

description: Supplemental Table 1: Sequencing spike-in sequences, concentrations, and total input.Supplemental Table 2: Alignment matrix detailing non-coding RNA mapping frequencies (percent total reads) for each sample.Supplemental Table 3: Alignment matrix detailing non-coding RNA mapping frequencies (total raw reads) for each sample.Supplemental Table 4: Normalized read counts for annotated non-coding RNA, excluding no-embryo control samples.Supplemental Figure 1: Spike-in sequencing metrics. The number of molecules of spike-in RNA added to a pool of 3 drops (left y-axis) compared to the measured level of spike-in sequences in reads per million (RPM; right y-axis), totaled across all samples. Per-sample measurements are available in Supplementary Table 1.Supplemental Figure 2: Principal component analysis with control samples excluded. ECCM samples cluster by pool size with single drop pools forming a separate cluster, suggesting that our limit of detection is 3 ECCM drops.
DOI: 10.6084/m9.figshare.11663340.v1
title: Metadata record for: Nexus of grazing management with plant and soil properties in northern China grasslands

description: This dataset contains key characteristics about the data described in the Data Descriptor Nexus of grazing management with plant and soil properties in northern China grasslands. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format
DOI: 10.6084/m9.figshare.11663301
title: Ex vivo cardiac DT-MRI rat study - LBNL

description: The ex vivo cardiac Diffusion Tensor MRI datasets of four healthy Wistar Kyoto rats (controls) and four spontaneously hypertensive rats (SHRs). All rats were male and their age during excision was 17-18 months old. The six tensor elements maps have been uploaded, together with MATLAB code to read the data, and a text file that describes the dataset dimensions. <br>Please cite the following paper if you use this dataset.<br>Giannakidis A. and Gullberg GT (2020). Transmural Remodelling of CardiacMicrostructure in Aged SpontaneouslyHypertensive Rats by Diffusion Tensor MRI. Frontiers in Physiology. 11:265. doi: 10.3389/fphys.2020.00265
DOI: 10.6084/m9.figshare.11663301.v1
title: Ex vivo cardiac DT-MRI rat study - LBNL

description: The ex vivo cardiac Diffusion Tensor MRI datasets of four healthy Wistar Kyoto rats (controls) and four spontaneously hypertensive rats (SHRs). All rats were male and their age during excision was 17-18 months old. The six tensor elements maps have been uploaded, together with MATLAB code to read the data, and a text file that describes the dataset dimensions. <br>Please cite the following paper if you use this dataset.<br>Giannakidis A. and Gullberg GT (2020). Transmural Remodelling of CardiacMicrostructure in Aged SpontaneouslyHypertensive Rats by Diffusion Tensor MRI. Frontiers in Physiology. 11:265. doi: 10.3389/fphys.2020.00265
DOI: 10.6084/m9.figshare.11663271
title: Supplementary Material for: Hidradenitis Suppurativa Influences Tattooing Practice in Women

description: <b><i>Background:</i></b> The reasons or the motivations that compel people to get a tattoo or a body piercing (BP) are plentiful and personal. Patients with chronic cutaneous or systemic conditions may be interested in getting tattooed or pierced. <b><i>Objective:</i></b> To determine the frequency of body art practices in hidradenitis suppurativa (HS) and to evaluate the possible impact of HS in the decision-making process. <b><i>Methods:</i></b> An anonymous specific paper-based questionnaire was prospectively offered to patients (≥18 years) consecutively managed for HS from September 2016 to March 2017 in a French specialized center. <b><i>Results:</i></b> In total, 209 patients participated in the study, of whom 77 (37%) and 50 (24%) had tattoos and BP, respectively. These proportions were higher than those reported in the French population. HS prevented the decision to get a BP or a tattoo in 2 and 5%, respectively (fear of infection or healing difficulties). Fifteen patients (7%) got tattooed to hide a surgical HS scar (<i>n</i> = 5, 2%), to regain control over the pain or their bodies (<i>n</i> = 9, 4%), or to turn others’ eyes away from HS lesions or scars (<i>n</i> = 1, 0.5%). HS severity influenced a proportion of patients who intended to get a new tattoo. <b><i>Conclusion:</i></b> HS is associated with a significant increase in body art practices.
DOI: 10.6084/m9.figshare.11663277
title: Data of patients entering a rehabilitation program

description: This is a data set made up of anagraphical, social and clinical records related to patient entered a rehabilitation program. Each record has further associated a performance measurement – called Barthel Index (BI) - which is widely recognized as a metric for assessing the Activities Daily Living (ADL) level.<br>The following files are made available:<br>- Dataset.csv: Raw dataset<br>- Cleaned_ Dataset.csv: dataset after preprocessing- Orthopedic.csv: dataset which refers only to orthopedic patients- Neurologial.csv: dataset with only neurological patients- Encoding Features.xlsx: tables to assign each code ICD9-CM to the corresponding clinical category<br>For more information about the data, please have a look at the scientific paper (More information in the following days)
DOI: 10.6084/m9.figshare.11663271.v1
title: Supplementary Material for: Hidradenitis Suppurativa Influences Tattooing Practice in Women

description: <b><i>Background:</i></b> The reasons or the motivations that compel people to get a tattoo or a body piercing (BP) are plentiful and personal. Patients with chronic cutaneous or systemic conditions may be interested in getting tattooed or pierced. <b><i>Objective:</i></b> To determine the frequency of body art practices in hidradenitis suppurativa (HS) and to evaluate the possible impact of HS in the decision-making process. <b><i>Methods:</i></b> An anonymous specific paper-based questionnaire was prospectively offered to patients (≥18 years) consecutively managed for HS from September 2016 to March 2017 in a French specialized center. <b><i>Results:</i></b> In total, 209 patients participated in the study, of whom 77 (37%) and 50 (24%) had tattoos and BP, respectively. These proportions were higher than those reported in the French population. HS prevented the decision to get a BP or a tattoo in 2 and 5%, respectively (fear of infection or healing difficulties). Fifteen patients (7%) got tattooed to hide a surgical HS scar (<i>n</i> = 5, 2%), to regain control over the pain or their bodies (<i>n</i> = 9, 4%), or to turn others’ eyes away from HS lesions or scars (<i>n</i> = 1, 0.5%). HS severity influenced a proportion of patients who intended to get a new tattoo. <b><i>Conclusion:</i></b> HS is associated with a significant increase in body art practices.
DOI: 10.6084/m9.figshare.11663250
title: Mouse embryo figures.rar

description: Morphogenetic comparison of freshly-dissected embryos with those at matching stages after 24 h in culture.
DOI: 10.6084/m9.figshare.11663232
title: Clinical interest of combining transcriptomic and genomic signatures in high-grade serous ovarian cancer

description: Data and R scripts used to generate the figures panels
DOI: 10.6084/m9.figshare.11663232.v1
title: Clinical interest of combining transcriptomic and genomic signatures in high-grade serous ovarian cancer

description: Data and R scripts used to generate the figures panels
DOI: 10.6084/m9.figshare.11663226
title: Table 1S_Complement Results of NIRS.docx

description: <b>Table 1S. </b>Comparison between three maximal intermittent exhaustion cycling tests in two situations [photobiomodulation therapy (PBMT) and placebo (PLA)] in five consecutive sections of each test (20, 40, 60, 80 and 100%) for NIRS percentage rest variables [oxyhemoglobin (O<sub>2</sub>Hb), deoxyhemoglobin (HHb), and total hemoglobin (tHb)]. Significant differences for p&lt;0.05 and Effect Size – ES&gt;0.80.
DOI: 10.6084/m9.figshare.11663226.v2
title: Table 1S_Complement Results of NIRS.docx

description: <b>Table 1S. </b>Comparison between three maximal intermittent exhaustion cycling tests in two situations [photobiomodulation therapy (PBMT) and placebo (PLA)] in five consecutive sections of each test (20, 40, 60, 80 and 100%) for NIRS percentage rest variables [oxyhemoglobin (O<sub>2</sub>Hb), deoxyhemoglobin (HHb), and total hemoglobin (tHb)]. Significant differences for p&lt;0.05 and Effect Size – ES&gt;0.80.
DOI: 10.6084/m9.figshare.11663226.v1
title: Table 1S_Complement Results of NIRS.docx

description: <b>Table 1S. </b>Comparison between three maximal intermittent exhaustion cycling tests in two situations [photobiomodulation therapy (PBMT) and placebo (PLA)] in five consecutive sections of each test (20, 40, 60, 80 and 100%) for NIRS percentage rest variables [oxyhemoglobin (O<sub>2</sub>Hb), deoxyhemoglobin (HHb), and total hemoglobin (tHb)]. Significant differences for p&lt;0.05 and Effect Size – ES&gt;0.80.
DOI: 10.6084/m9.figshare.11663148
title: List of selected metabolites that satisfied the following criteria at q-value &lt; 0.05: 1) when CN was compared to AN at week 1 or 2, and 2) when CN was compared to CN-C or AN between week 4 to 12.

description: In total, 504 metabolites met the marker selection criteria.<br>AN, acute nephritis; AN-C, control group for acute nephritis; CN, chronic nephritis; CN-C, control group for chronic nephritis.
DOI: 10.6084/m9.figshare.11663148.v1
title: List of selected metabolites that satisfied the following criteria at q-value &lt; 0.05: 1) when CN was compared to AN at week 1 or 2, and 2) when CN was compared to CN-C or AN between week 4 to 12.

description: In total, 504 metabolites met the marker selection criteria.<br>AN, acute nephritis; AN-C, control group for acute nephritis; CN, chronic nephritis; CN-C, control group for chronic nephritis.
DOI: 10.6084/m9.figshare.11663145
title: Supplementary Material for: Dry Fasting Physiology: Responses to Hypovolemia and Hypertonicity

description: <b><i>Objective:</i></b> The aim of this study was to provide a deeper insight into dry fasting (DF) physiology. <b><i>Design:</i></b> Ten participants performed DF for 5 consecutive days. <b><i>Methods:</i></b> The following parameters were monitored daily: cortisol, aldosterone, high-sensitivity C-reactive protein (CRP), erythropoietin, albumin, uric acid, and vitamin C in serum; vasopressin (ADH), adrenocorticotropic hormone (ACTH), renin, angiotensin II, and total antioxidant capacity (TAC) in plasma; hematocrit and erythrocytes in whole blood; osmolality, noradrenaline, dopamine, adrenaline, Na<sup>+</sup>, and K<sup>+</sup> in 24-h urine; waist circumference and body, urine, and stool weight. <b><i>Results:</i></b> The following parameters increased: ADH (60 ± 11%), ACTH (176 ± 34%), cortisol (495 ± 75%), urine osmolality (20 ± 4%), CRP (167 ± 77%), renin (315 ± 63%), angiotensin II (74 ± 21%), aldosterone (61 ± 21%), TAC (80.4 ± 17%), uric acid (103 ± 19%), albumin (18.4 ± 2.4%), erythrocytes (13.4 ± 2.2%), hematocrit (11 ± 1.8%), and the excretion of noradrenaline (40.3 ± 10%) and dopamine (17 ± 5%). The following parameters decreased: waist circumference (8.20 ± 0.61 cm), body weight (7.010 ± 0.3 kg), erythropoietin (65 ± 18%), and the excretion of adrenaline (38 ± 4%) and Na<sup>+</sup> (60 ± 16%). The excretion of K<sup>+</sup> remained unchanged. Vitamin C decreased, showing a half-life of 4.8 ± 0.7 days. The percent ratios of lost weight components were: urine (52.2 ± 3.7%), insensible water loss (32.2 ± 1.4%), stool (5 ± 0.3%), and respiratory gases, i.e., expired CO<sub>2</sub> – incorporated O<sub>2</sub> (10.6 ± 5.4%). <b><i>Conclusion:</i></b> The mechanisms underlying the hypertonicity and hypovolemia compensation and the ratio analysis of lost weight components were presented. DF demonstrated short-term antioxidant, anti-ischemic, immune-stimulating, anti-edematous, and anti-inflammatory effects. The results may have an impact on developing new concepts for the treatment of edema, obesity, and inflammatory and ischemic diseases.
DOI: 10.6084/m9.figshare.11663145.v1
title: Supplementary Material for: Dry Fasting Physiology: Responses to Hypovolemia and Hypertonicity

description: <b><i>Objective:</i></b> The aim of this study was to provide a deeper insight into dry fasting (DF) physiology. <b><i>Design:</i></b> Ten participants performed DF for 5 consecutive days. <b><i>Methods:</i></b> The following parameters were monitored daily: cortisol, aldosterone, high-sensitivity C-reactive protein (CRP), erythropoietin, albumin, uric acid, and vitamin C in serum; vasopressin (ADH), adrenocorticotropic hormone (ACTH), renin, angiotensin II, and total antioxidant capacity (TAC) in plasma; hematocrit and erythrocytes in whole blood; osmolality, noradrenaline, dopamine, adrenaline, Na<sup>+</sup>, and K<sup>+</sup> in 24-h urine; waist circumference and body, urine, and stool weight. <b><i>Results:</i></b> The following parameters increased: ADH (60 ± 11%), ACTH (176 ± 34%), cortisol (495 ± 75%), urine osmolality (20 ± 4%), CRP (167 ± 77%), renin (315 ± 63%), angiotensin II (74 ± 21%), aldosterone (61 ± 21%), TAC (80.4 ± 17%), uric acid (103 ± 19%), albumin (18.4 ± 2.4%), erythrocytes (13.4 ± 2.2%), hematocrit (11 ± 1.8%), and the excretion of noradrenaline (40.3 ± 10%) and dopamine (17 ± 5%). The following parameters decreased: waist circumference (8.20 ± 0.61 cm), body weight (7.010 ± 0.3 kg), erythropoietin (65 ± 18%), and the excretion of adrenaline (38 ± 4%) and Na<sup>+</sup> (60 ± 16%). The excretion of K<sup>+</sup> remained unchanged. Vitamin C decreased, showing a half-life of 4.8 ± 0.7 days. The percent ratios of lost weight components were: urine (52.2 ± 3.7%), insensible water loss (32.2 ± 1.4%), stool (5 ± 0.3%), and respiratory gases, i.e., expired CO<sub>2</sub> – incorporated O<sub>2</sub> (10.6 ± 5.4%). <b><i>Conclusion:</i></b> The mechanisms underlying the hypertonicity and hypovolemia compensation and the ratio analysis of lost weight components were presented. DF demonstrated short-term antioxidant, anti-ischemic, immune-stimulating, anti-edematous, and anti-inflammatory effects. The results may have an impact on developing new concepts for the treatment of edema, obesity, and inflammatory and ischemic diseases.
DOI: 10.6084/m9.figshare.11663136
title: Supplementary Material for: Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents

description: <b><i>Background:</i></b> Ozenoxacin is a topical antibiotic approved in Europe to treat non-bullous impetigo in adults and children aged ≥6 months. This analysis evaluated the efficacy and safety of ozenoxacin in paediatric patients by age group. <b><i>Methods:</i></b> Pooled data for patients aged 6 months to &lt;18 years who had participated in a phase I or in two phase III clinical trials of ozenoxacin 1% cream were analysed by age group: 0.5–&lt;2, 2–&lt;6, 6–&lt;12, and 12–&lt;18 years. <b><i>Results:</i></b> The combined population comprised 529 patients with non-bullous impetigo treated with ozenoxacin (<i>n</i> = 239), vehicle (<i>n</i> = 201), or retapamulin as internal validation control (<i>n</i> = 89). Studies were well matched for extent and severity of impetigo and therapeutic schedule (twice daily application for 5 days). The clinical success rate after 5 days’ treatment (day 6–7, end of therapy), and microbiological success rates after 3–4 days’ treatment and at the end of therapy, were significantly higher with ozenoxacin than vehicle (<i>p</i> &lt; 0.0001 for all comparisons). Clinical and bacterial eradication rates were higher with ozenoxacin than vehicle in each age group. No safety concerns were identified with ozenoxacin. One (0.3%) of 327 plasma samples exceeded the lower limit of quantification for ozenoxacin, but the low concentration indicated negligible systemic absorption. <b><i>Conclusion:</i></b> This combined analysis supports the efficacy and safety of ozenoxacin administered twice daily for 5 days. Ozenoxacin 1% cream is a new option to consider for treatment of non-bullous impetigo in children aged 6 months to &lt;18 years.
DOI: 10.6084/m9.figshare.11663136.v1
title: Supplementary Material for: Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents

description: <b><i>Background:</i></b> Ozenoxacin is a topical antibiotic approved in Europe to treat non-bullous impetigo in adults and children aged ≥6 months. This analysis evaluated the efficacy and safety of ozenoxacin in paediatric patients by age group. <b><i>Methods:</i></b> Pooled data for patients aged 6 months to &lt;18 years who had participated in a phase I or in two phase III clinical trials of ozenoxacin 1% cream were analysed by age group: 0.5–&lt;2, 2–&lt;6, 6–&lt;12, and 12–&lt;18 years. <b><i>Results:</i></b> The combined population comprised 529 patients with non-bullous impetigo treated with ozenoxacin (<i>n</i> = 239), vehicle (<i>n</i> = 201), or retapamulin as internal validation control (<i>n</i> = 89). Studies were well matched for extent and severity of impetigo and therapeutic schedule (twice daily application for 5 days). The clinical success rate after 5 days’ treatment (day 6–7, end of therapy), and microbiological success rates after 3–4 days’ treatment and at the end of therapy, were significantly higher with ozenoxacin than vehicle (<i>p</i> &lt; 0.0001 for all comparisons). Clinical and bacterial eradication rates were higher with ozenoxacin than vehicle in each age group. No safety concerns were identified with ozenoxacin. One (0.3%) of 327 plasma samples exceeded the lower limit of quantification for ozenoxacin, but the low concentration indicated negligible systemic absorption. <b><i>Conclusion:</i></b> This combined analysis supports the efficacy and safety of ozenoxacin administered twice daily for 5 days. Ozenoxacin 1% cream is a new option to consider for treatment of non-bullous impetigo in children aged 6 months to &lt;18 years.
DOI: 10.6084/m9.figshare.11663097
title: "Angiosperm speciation cools down in the tropics" scripts

description: R scripts to generate analyses and crude versions of the plots for the manuscript "Angiosperm speciation cools down in the tropics" by Javier Igea and Andrew Tanentzap<br><br>
DOI: 10.6084/m9.figshare.11663076
title: Metadata record for: All-hazards dataset mined from the US National Incident Management System 1999-2014

description: This dataset contains key characteristics about the data described in the Data Descriptor All-hazards dataset mined from the US National Incident Management System 1999-2014. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format <br><b><br></b>Versioning Note:Version 2 was generated when the metadata format was updated from JSON to JSON-LD. This was an automatic process that changed only the format, not the contents, of the metadata.<br>
DOI: 10.6084/m9.figshare.11663076.v2
title: Metadata record for: All-hazards dataset mined from the US National Incident Management System 1999-2014

description: This dataset contains key characteristics about the data described in the Data Descriptor All-hazards dataset mined from the US National Incident Management System 1999-2014. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format <br><b><br></b>Versioning Note:Version 2 was generated when the metadata format was updated from JSON to JSON-LD. This was an automatic process that changed only the format, not the contents, of the metadata.<br>
DOI: 10.6084/m9.figshare.11663076.v1
title: Metadata record for: All-hazards dataset mined from the US National Incident Management System 1999-2014

description: This dataset contains key characteristics about the data described in the Data Descriptor All-hazards dataset mined from the US National Incident Management System 1999-2014. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format
DOI: 10.6084/m9.figshare.11663061
title: merged.xlsx

description: international trade war spillovers<br>
DOI: 10.6084/m9.figshare.11663061.v1
title: merged.xlsx

description: international trade war spillovers<br>
DOI: 10.6084/m9.figshare.11662959
title: Metadata record for: High-resolution T2-FLAIR and non-contrast CT brain atlas of the elderly

description: This dataset contains key characteristics about the data described in the Data Descriptor High-resolution T2-FLAIR and non-contrast CT brain atlas of the elderly. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format <br> <br> Versioning Note:Version 2 was generated when the metadata format was updated from JSON to JSON-LD. This was an automatic process that changed only the format, not the contents, of the metadata.<br>
DOI: 10.6084/m9.figshare.11662959.v2
title: Metadata record for: High-resolution T2-FLAIR and non-contrast CT brain atlas of the elderly

description: This dataset contains key characteristics about the data described in the Data Descriptor High-resolution T2-FLAIR and non-contrast CT brain atlas of the elderly. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format <br> <br> Versioning Note:Version 2 was generated when the metadata format was updated from JSON to JSON-LD. This was an automatic process that changed only the format, not the contents, of the metadata.<br>
DOI: 10.6084/m9.figshare.11662950
title: Brain abscess: clinical, radiological and microbiological data for a retrospective UK cohort

description: These files are the supporting metadata for a retrospective analysis of a clinical cohort of adults with a diagnosis of bacterial brain abscess at Oxford University Hospitals NHS Foundation Trust, in the UK. The study was locally approved as a clinical audit.<br>The xls file contains the clinical metadata reported by our study.<br>We have provided a STROBE statement (Strengthening the Reporting of Observational Studies in Epidemiology)<br>The supplementary data file (pdf) contains the following information:<br><b>Suppl Figure 1: </b>CONSORT diagram for identification of a cohort of adults with brain abscesses from a tertiary referral hospital in the UK. <br><b>Suppl Fig 2: </b>Duration of antibiotic therapy for adults treated for bacterial brain abscess<br><b>Suppl Table 1: </b>Association between S. milleri infection and other patient characteristics in a cohort of 39 adults with positive microbiology diagnosis of bacterial brain abscess<br><b>Suppl Table 2</b>: Number of surgical interventions undertaken for 47 adults presenting with brain abscess<br>
DOI: 10.6084/m9.figshare.11662959.v1
title: Metadata record for: High-resolution T2-FLAIR and non-contrast CT brain atlas of the elderly

description: This dataset contains key characteristics about the data described in the Data Descriptor High-resolution T2-FLAIR and non-contrast CT brain atlas of the elderly. <br> Contents: <br> 1. human readable metadata summary table in CSV format 2. machine readable metadata file in JSON format <br> <br> <br>